This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

The present invention relates to bispecific antibodies comprising a modified C-terminal crossfab fragment that have reduced or no reactivity against preexisting antidrug antibodies.

In alternative embodiments, provided are chimeric immunogens or antigens, and methods for making and using them, including methods for making and obtaining polyclonal antibodies specific for selected epitopes. In alternative embodiments, provided are methods for generating an epitope-specific antibody response in a rabbit, wherein the immune response comprises generation of rabbit antibodies specifically against (or that specifically bind to) at least one human epitope, and the method comprises administering to a rabbit a sufficient amount of a chimeric or recombinant polypeptide to generate the epitope-specific antibody response. In alternative embodiments, provided are chimeric or recombinant polypeptides comprising: a ferritin polypeptide having conjugated or attached thereto by or via a substantially non-immunogenic linker an immunogenic peptide or polypeptide.

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

Provided is an antibody that has a high binding activity to membrane-bound IgM on the surface of B cells and exhibits a growth inhibition effect on the B cells, even in the presence of soluble IgM in blood. A bispecific antibody, which binds to IgM and a B cell surface antigen.

In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a CD9B441 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include CD9B441.

Herein is reported a method for determining the epitope of an antibody specifically binding to a therapeutic antibody comprising the steps of a) incubating a sample, which comprises serum and the antibody specifically binding to a therapeutic antibody, separately with i) at least a Fab fragment of the therapeutic antibody, and ii) at least a Fab fragments of the therapeutic antibody in which the HVRs forming a paratope have been replaced with germline sequences, and detecting the binding or non-binding of the antibody specifically binding to a therapeutic antibody to the at least a Fab fragment in any of i) to ii), and b) determining the epitope of the antibody specifically binding to a therapeutic antibody to be in the at least one HVR that has been replaced in ii) if binding is detected in i) and non-binding is detected in ii).

Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

The present disclosure relates to methods of re-oxidizing an antigen-binding protein.

The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.